DIM Detox 60c Pure Encapsulations

DIM Detox 60c

Pure Encapsulations

$55.40
(No reviews yet) Write a Review
SKU:
PUR-P13589
Availability:
Usually Ships in 48 to 72 Hours
Already Registered?
How to Gain Access to Store?

DIM Detox 60c by Pure Encapsulations 

DIM Detox 60c is a women’s health supplement designed by Pure Encapsulations with the goal of supporting natural detoxification and cellular health.* It may help you address symptoms such as: fatigue, headaches, or bloating.* Moreover, it supports the liver in processing toxins and nutrient absorption.*

Who May Take DIM Detox 60c by Pure Encapsulations?

DIM Detox 60c may support your health if you:

  • want to balance your estrogen levels*
  • suffer from fatigue, bloating, or headaches*
  • desire a fully vegan supplement*

DIM Detox 60c—Effects

DIM Detox 60c may support you with:

  • maintaining regular estrogen levels*
  • phase II detoxification*
  • transporting energy and nutrients to your cells*
  • estrogen metabolism*

Supplements support your health but do not replace a balanced diet. Always check with your healthcare practitioner if you have doubts about a new supplement. Book a FREE product consultation to learn more about DIM Detox 60c.

Recommendation: 
Pure Encapsulations suggests taking 2 capsules with meals, or as directed by a healthcare professional. 

Serving Size: 2 Capsules
Servings per Container: 30

Amount Per Serving:
BioResponse DIM® diindolylmethane complex 100 mg 
(complex of starch, diindolylmethane, d-alpha tocopheryl succinate, phosphatidylcholine and silica)
(standardized to contain 25% diindolylmethane)
Calcium-d-glucarate 100 mg 
Broccoli (brassica oleracea italica) sprout 100 mg 
concentrate (whole plant)
(standardized to contain a minimum of 400 mcg sulforaphane)
HMRlignan 7-hydroxymatairesinol 10 mg 
(Norway spruce)
Alpha lipoic acid (thioctic acid) 200 mg 
N-acetyl-l-cysteine (free-form) 200 mg 
Milk thistle (silybum marianum) extract 150 mg 
(fruit) (standardized to contain 80% silymarin)
L-methionine (free-form) 200 mg 
Glycine (free-form) 100 mg 
Taurine (free-form) 100 mg

Other Ingredients: hypo-allergenic plant fiber, vegetable capsule, ascorbyl palmitate

Caution: If you are pregnant or lactating, have any health condition or are taking any medication, consult your health professional before use.

Storage: Store in a cool, dry place. 

Pure Encapsulations’ logo, text, graphics, and photo images are the property of Société des Produits Nestlé S.A. and are used with permission. Copyright © 2021.

*These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.

Click here to view Product Info Sheet

References:

  1. Riby, J. E., Chang, G. H., Firestone, G. L., & Bjeldanes, L. F. (2000). Ligand-independent activation of estrogen receptor function by 3,3'-diindolylmethane in human breast cancer cells. Biochemical Pharmacology, 60(2), 167-177.
  2. Michnovicz, J. J. (1998). Increased estrogen 2-hydroxylation in obese women using oral indole-3-carbinol. International Journal of Obesity and Related Metabolic Disorders, 22(3), 227-229.
  3. Oredipe, O. A., Lechner, J. F., & Steele, V. E. (1992). Effects of chemopreventive agents on cytochrome P450 1A1 and glutathione S-transferase activities in cultured rat hepatocytes. Toxicology, 74(2-3), 209-222.
  4. Rodriguez-Leyva, D., Dupasquier, C. M. C., McCullough, R., & Pierce, G. N. (2013). The cardiovascular effects of flaxseed and its omega-3 fatty acid, alpha-linolenic acid. Hypertension, 62(6), 1081-1089.
  5. Thompson, L. U., Chen, J. M., Li, T., Strasser-Weippl, K., & Goss, P. E. (2005). Dietary flaxseed alters tumor biological markers in postmenopausal breast cancer. Clinical Cancer Research, 11(10), 3828-3835.
  6. Spence, J. D., Thornton, T., Muir, A. D., & Westcott, N. D. (2003). The effect of flaxseed cultivars with differing content of alpha-linolenic acid and lignans on markers of early atherosclerosis. Journal of the American College of Nutrition, 22(6), 494-501.
  7. Ferenci, P., Dragosics, B., Dittrich, H., Frank, H., Gangl, A., Herbst, F., ... & Wewalka, F. (1989). Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. Journal of Hepatology, 9(1), 105-113.
  8. Flier, J. S., Underhill, L. H., & Cannon, P. J. (2002). Obesity, fat distribution, and metabolic disease: Implications for the treatment of hyperlipidemia. Free Radical Research, 36(6), 695-702.
  9. Kaplan, M., Aviram, M., & Hayek, T. (2008). Oxidative stress and macrophage foam cell formation during hyperlipidemia in ECT/ETC-deficient mice. Pediatric Nephrology, 23(2), 233-241.
  10. Wang, W. Y., Ho, L. T., Chao, C. H., & Kuo, P. H. (1991). Effects of oral L-carnitine supplementation on lipid metabolism in patients on chronic hemodialysis. JPEN Journal of Parenteral and Enteral Nutrition, 15(3), 294-297.
  11. Deters, M., Strubelt, O., Pentz, R., & Holzinger, H. (1998). Endotoxin-induced liver injury and its prevention by carnitine in the rat. Toxicology, 128(1), 63-72.
  12. Krüger, H., Wilke, A., Arend, J., & Gessner, H. (1997). Chromium supplements in healthy volunteers—Effects on glucose tolerance, insulin sensitivity, and serum lipids. General Pharmacology, 28(2), 257-263.